• Publications
  • Influence
Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or “Ecstasy”)
It is suggested that the recent increase in the number of reports of MDMA toxicity probably results from the widespread use of the drug at all night dance parties or “raves”, and suggestions for the rational treatment of the acute toxicity are made on the basis of both pharmacological studies in animals and current clinical practice. Expand
Frontal Cortical and Left Temporal Glutamatergic Dysfunction in Schizophrenia
The results suggest that schizophrenia may involve left‐sided abnormalities in the relationship between temporal glutamatergic and dopaminergic projections to amygdala, and are compatible with an overabundant glutamatorgic innervation of orbital frontal cortex in schizophrenia. Expand
Increased dopamine-receptor sensitivity was present in five patients who had been free of neuroleptic medication for at least 1 year before death, and therefore may be related to the disease process. Expand
Spontaneous orofacial dyskinesia and dopaminergic function in rats after 6 months of neuroleptic treatment.
A syndrome of spontaneous orofacial dyskinesia was identified in groups of rats treated for 6 months with a wide range of neuroleptic drugs, whose pathophysiology thus may not involve changes in the characteristics of striatal dopamine receptors. Expand
Serotonin in Alzheimer‐type Dementia and Other Dementing Illnesses
  • A. Cross
  • Medicine
  • Annals of the New York Academy of Sciences
  • 1 October 1990
By studying serotonergic mechanisms in these diseases in comparison with ATD it may be possible to determine which features of the disease are likely to be associated withSerotonergic deficits, and whether these features are associated with depression, agitation and aggression. Expand
Effect of NXY‐059 on infarct volume after transient or permanent middle cerebral artery occlusion in the rat; studies on dose, plasma concentration and therapeutic time window
The data demonstrate the substantial neuroprotective efficacy of N XY‐059 at plasma concentrations that can be achieved clinically and indicate that NXY‐059 also has a therapeutic window of opportunity that is clinically relevant. Expand
The central nervous system effects of the partial GABA-Aα2,3 -selective receptor modulator AZD7325 in comparison with lorazepam in healthy males.
The characteristic ΔSPV-relative effect profiles of AZD7325 vs. lorazepam suggest anxio-selectivity related to α2,3 -selective GABAA agonism, with potentially lower cognitive and neurophysiological side effect burden than non-selective benzodiazepines. Expand
Neurotransmitter receptors and monoamine metabolites in the brains of patients with Alzheimer-type dementia and depression, and suicides
In patients dying in hospital with depression, and in individuals committing suicide, there are no consistent changes in monoamine metabolites, and noradrenergic, serotonergic, and other neurotransmitter receptors were found to be unchanged, although there was a moderate decrease in imipramine binding in a small group of subjects with a history of depression. Expand
Animal models of acute ischaemic stroke: can they predict clinically successful neuroprotective drugs?
The major models of acute cerebral ischaemia are reviewed, and rational protocols for examining novel neuroprotective agents are proposed. Expand
The selectivity of the reduction of serotonin S2 receptors in Alzheimer-type dementia
The high-affinity binding of thirteen ligands to putative neurotransmitter receptors was studied in temporal cortex of control and Alzheimer-type dementia (ATD) patients. A selective reduction ofExpand